Eisai Aricept (donepezil) shows no hepatotoxicity in Phase III trials; NDA filed March 29.
Executive Summary
EISAI ARICEPT FOR ALZHEIMER's SHOWS NO HEPATOTOXICITY, according to a company presentation of Phase III data at the American Academy of Neurology meeting in San Francisco March 26. Tokyo-based Eisai announced that Eisai America filed an NDA for Aricept (donepezil, E2020) on March 29. The filing is on schedule with the goal discussed by U.S. co-promotion partner Pfizer in 1994 ("The Pink Sheet" Dec. 5, 1994, T&G-5). Pfizer Exec VP Henry McKinnell said at a Financial Times conference in London that the NDA for the selective acetylcholinesterase inhibitor may get accelerated registration at FDA.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth